09:40 AM EDT, 08/25/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) down 10% on last look, on Monday said it has been awarded a research grant of US$2 million by the National Cancer Institute (NCI) in the U.S., to advance Bria-PROS+, the company's newest personalized off-the-shelf immunotherapy for prostate cancer.

The grant will fund the upcoming Phase 1/2a study in patients with advanced prostate cancer and complete manufacturing of Bria-Pros+ clinical supply, a statement said.

"The Bria-OTS+ platform was designed to overcome the complexity, cost and delays of traditional personalized cancer treatments," said Miguel Lopez-Lago, BriaCell's chief scientific officer. "We believe it will constitute a significant advancement in personalized cancer care."

BriaCell is down $0.93, to $8.57, on the Toronto Stock Exchange.

Price: 9.15, Change: -0.35, Percent Change: -3.68